Want to see IN:VIMTALABS full AI Analyst Report?
Top Page
Vimta Labs Limited
(VIMTALABS)
Select Model
Select Model
Rating:67Neutral
Price Target:
₹530.00
▼(-13.01% Downside)
Action:Downgraded
Date:10/22/26
The score is primarily driven by strong underlying financial quality—solid profitability and a very low-leverage balance sheet—partly offset by inconsistent margin/FCF history. Near-term risk is elevated due to weak technicals (price below all key moving averages and bearish MACD), while valuation is only moderate with a relatively high P/E and low dividend yield.
Positive Factors
Revenue Growth and Profitability
Sustained multi-year revenue growth alongside healthy net and EBITDA margins indicates established demand for Vimta Labs’ testing and research services. This combination supports internal reinvestment, strengthens operating resilience, and provides a durable base for continued expansion across regulated end markets.
Negative Factors
Margin Volatility
Volatile gross and operating margins suggest that service mix, costs, or utilization can materially affect profitability. Even with healthy current margins, this variability makes earnings quality less predictable and may limit confidence that present profitability levels will persist through changing business conditions.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth and Profitability
Sustained multi-year revenue growth alongside healthy net and EBITDA margins indicates established demand for Vimta Labs’ testing and research services. This combination supports internal reinvestment, strengthens operating resilience, and provides a durable base for continued expansion across regulated end markets.
Read all positive factors
Vimta Labs Limited (VIMTALABS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹21.67B
Dividend Yield0.41%
Average Volume (3M)9.83K
Price to Earnings (P/E)27.1
Beta (1Y)1.07
Revenue Growth14.22%
EPS Growth7.17%
CountryIN
Employees1,384
SectorGeneral
Sector StrengthN/A
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)17.86
Shares Outstanding44,699,860
10 Day Avg. Volume7,772
30 Day Avg. Volume9,826
Financial Highlights & Ratios
PEG Ratio1.47
Price to Book (P/B)3.71
Price to Sales (P/S)4.16
P/FCF Ratio34.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)20.1
Revenue Forecast (FY)₹4.64B
Vimta Labs Limited Business Overview & Revenue Model
Company Description
Vimta Labs Limited provides specialized contract research and analytical testing services, operating both within India and internationally. Their extensive offerings encompass general laboratory analyses, comprehensive food and water quality testi...
How the Company Makes Money
Vimta Labs makes money primarily by charging customers for laboratory testing and related technical services delivered under contractual engagements. Key revenue streams include: (1) Analytical and quality testing fees: recurring and project-based...
Vimta Labs Limited Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
90
Very Positive
Cash Flow
72
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.19B | 4.07B | 3.44B | 3.18B | 3.15B | 2.76B |
| Gross Profit | 2.11B | 1.58B | 1.33B | 2.42B | 2.41B | 914.08M |
| EBITDA | 1.55B | 1.43B | 1.26B | 902.01M | 966.38M | 802.74M |
| Net Income | 796.61M | 775.12M | 673.42M | 410.09M | 481.72M | 413.30M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 5.62B | 4.67B | 4.00B | 3.62B | 3.07B |
| Cash, Cash Equivalents and Short-Term Investments | 664.70M | 670.61M | 327.21M | 256.01M | 395.73M | 112.06M |
| Total Debt | 0.00 | 33.32M | 85.15M | 191.89M | 149.88M | 193.41M |
| Total Liabilities | -4.57B | 1.05B | 876.84M | 803.54M | 805.39M | 732.14M |
| Stockholders Equity | 4.57B | 4.57B | 3.79B | 3.20B | 2.82B | 2.34B |
Cash Flow | ||||||
| Free Cash Flow | 270.48M | 489.82M | 157.66M | -156.78M | 381.32M | 203.45M |
| Operating Cash Flow | 748.73M | 1.49B | 948.30M | 608.92M | 879.37M | 590.69M |
| Investing Cash Flow | -558.92M | -1.32B | -755.37M | -760.48M | -572.56M | -378.48M |
| Financing Cash Flow | -66.76M | -98.43M | -166.81M | -19.03M | -109.81M | -166.14M |
Vimta Labs Limited Technical Analysis
Negative
609.25
Price Trends
583.13
Negative
583.47
Negative
524.84
Negative
Market Momentum
-25.48
Negative
34.25
Neutral
61.29
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VIMTALABS, the sentiment is Negative. The current price of 609.25 is above the 20-day moving average (MA) of 525.95, above the 50-day MA of 583.13, and above the 200-day MA of 524.84, indicating a bearish trend. The MACD of -25.48 indicates Negative momentum. The RSI at 34.25 is Neutral, neither overbought nor oversold. The STOCH value of 61.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:VIMTALABS.
Vimta Labs Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | ₹319.97B | 58.77 | ― | 0.84% | 14.29% | 5.55% | |
71 Outperform | ₹149.06B | 79.30 | ― | 0.14% | 20.18% | 24.71% | |
67 Neutral | ₹21.67B | 27.15 | ― | 0.41% | 14.22% | 7.17% | |
63 Neutral | ₹72.74B | 50.42 | ― | 2.04% | 21.99% | 12.77% | |
61 Neutral | ₹16.35B | 16.77 | ― | 0.40% | 10.19% | 20.99% | |
59 Neutral | ₹113.09B | 56.06 | ― | 0.37% | 21.80% | 31.84% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
IN:VIMTALABS
Vimta Labs Limited
484.85
-237.74
-32.90%
IN:KRSNAA
Krsnaa Diagnostics Limited
504.10
-268.69
-34.77%
IN:LALPATHLAB
Dr. Lal PathLabs Limited
1,906.30
353.10
22.73%
IN:METROPOLIS
Metropolis Healthcare Ltd.
545.15
55.73
11.39%
IN:THYROCARE
Thyrocare Technologies Ltd
457.00
-2.55
-0.55%
IN:VIJAYA
Vijaya Diagnostic Centre Ltd.
1,447.25
462.37
46.95%
Vimta Labs Limited Corporate Events
Vimta Labs Closes Trading Window Ahead of September Quarter Results
Sep 30, 2026
Vimta Labs Limited has announced the closure of its trading window for company shares for all designated persons, their immediate relatives, and connected individuals under its insider trading prevention code, in line with SEBI (Prohibition of Ins...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.